Tisento Therapeutics Email Formats

Biotechnology Research • United States • 11-20 Employees

Tisento Therapeutics Email Formats

Tisento Therapeutics uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@tisentotx.com), used 66.7% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@tisentotx.com	66.7%
{first initial}	j@tisentotx.com	33.3%

Key Contacts at Tisento Therapeutics

Peter Hecht

Chief Executive Officer

Sara Ciarametaro

Sr Director Finance And Operations

Company overview

Headquarters	United States
Website	tisentotx.com
NAICS	541714
Keywords	Drug Development, Rare Disease, Mitochondrial Disease, Melas
Founded	2023
Employees	11-20
Socials

About Tisento Therapeutics

Ti sento means “I hear you" in Italian. At Tisento Therapeutics, we believe that meaningful innovation requires understanding the problem, and that starts with listening. First and foremost, we listen to those impacted by debilitating diseases to understand the daily challenges they face. We also listen to healthcare providers, patient advocates, regulatory agencies, and scientific data. All these inputs inform our thinking and shape how we conduct our research, design our trials, and evolve our company. We are on a mission to deliver medicines that address what matters most. Our lead candidate is zagociguat (formerly CY6463), a Phase 2, first-in-class, brain-penetrant sGC stimulator, which is advancing in MELAS and other genetic mitochondrial diseases. Zagociguat is ideally suited to treat mitochondrial diseases with both CNS and peripheral symptoms, such as cognitive impairment, fatigue, and muscle weakness.

Employees by Management Level

Total employees: 11-20

Seniority

Employees

Vice President

Entry

C-Suite

Employees by Department

Tisento Therapeutics has 9 employees across 7 departments.

Departments

Number of employees

Funding Data

Explore Tisento Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2023-08-31	4	$81,000,000

Funding Insights

$81,000,000

Total funding amount

$81,000,000

Most recent funding amount

Number of funding rounds

Tisento Therapeutics Tech Stack

Discover the technologies and tools that power Tisento Therapeutics's digital infrastructure, from frameworks to analytics platforms.

Adobe Fonts

Font scripts

Modernizr

JavaScript libraries

Lodash

JavaScript libraries

reCAPTCHA

Security

Squarespace Commerce

Ecommerce

Stimulus

JavaScript frameworks

HSTS

Security

Open Graph

Miscellaneous

Elfsight

Widgets

core-js

JavaScript libraries

HubSpot

Marketing automation

Cart Functionality

Ecommerce

Frequently asked questions

Tisento Therapeutics is located in US.

Tisento Therapeutics was founded in 2023, making it 3 years old. The company has established itself as a significant player in its industry over this time.

Tisento Therapeutics has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.

Tisento Therapeutics has raised a total of $81,000,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.

Key Contacts at Tisento Therapeutics

Peter Hecht

Chief Executive Officer

Sara Ciarametaro

Sr Director Finance And Operations

4.8

40,000 users